Published in Pharmaceuticals (Basel) on July 21, 2010
Evaluation of anti-inflammatory activity of selected medicinal plants used in Indian traditional medication system in vitro as well as in vivo. J Tradit Complement Med (2015) 0.77
Inhaled nitric oxide prevents NSAID-induced renal impairment in pseudo-normovolaemic piglets. PLoS One (2017) 0.75
Characterisation of Drug-Related Problems and Associated Factors at a Clinical Pharmacist Service-Naïve Hospital in Northern Sweden. Drugs Real World Outcomes (2017) 0.75
Spinal manipulative therapy for low back pain-time for an update. Can Fam Physician (2017) 0.75
Mathematical deconvolution uncovers the genetic regulatory signal of cancer cellular heterogeneity on resistance to paclitaxel. Mol Genet Genomics (2017) 0.75
Concern Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med (2000) 29.03
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med (1994) 4.64
Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum (2005) 4.63
Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell (1995) 4.47
Renal failure in cirrhosis. N Engl J Med (2009) 4.46
Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell (1995) 4.17
Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA (2006) 4.04
Cellular and subcellular immunolocalization of vasopressin-regulated water channel in rat kidney. Proc Natl Acad Sci U S A (1993) 3.82
Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature (1995) 3.44
Acetaminophen, aspirin, and chronic renal failure. N Engl J Med (2001) 3.28
Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis (2000) 3.09
Paracrine regulation of the renal microcirculation. Physiol Rev (1996) 2.86
Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med (2000) 2.82
Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev (2007) 2.75
Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med (1994) 2.74
Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol (2008) 2.63
Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest (1994) 2.55
Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J (2001) 2.52
Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med (1991) 2.40
Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol (2002) 2.38
Occupational and other exposures associated with male end-stage renal disease: a case/control study. Am J Public Health (1990) 2.26
Analgesic use and chronic renal disease. N Engl J Med (1989) 2.12
NSAID prescribing precautions. Am Fam Physician (2009) 2.04
Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest (2006) 2.03
Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles. Mol Pharmacol (2009) 2.00
Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med (1999) 2.00
Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl (1999) 1.97
Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci (2008) 1.94
Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med (2004) 1.91
Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int (2002) 1.90
Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest (2002) 1.86
COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov (2003) 1.82
Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med (1999) 1.81
NSAID use and progression of chronic kidney disease. Am J Med (2007) 1.75
Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab (1979) 1.75
The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med (2005) 1.72
A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med (1993) 1.68
Role for thromboxane receptors in angiotensin-II-induced hypertension. Hypertension (2004) 1.57
Low chloride stimulation of prostaglandin E2 release and cyclooxygenase-2 expression in a mouse macula densa cell line. J Biol Chem (2000) 1.57
Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology (2005) 1.53
Luminal NaCl delivery regulates basolateral PGE2 release from macula densa cells. J Clin Invest (2003) 1.49
Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med (2005) 1.49
Indomethacin in the treatment of lithium-induced nephrogenic diabetes insipidus. Arch Intern Med (1989) 1.46
Cyclooxygenase metabolites mediate glomerular monocyte chemoattractant protein-1 formation and monocyte recruitment in experimental glomerulonephritis. Kidney Int (1999) 1.45
Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol (1997) 1.45
Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf (2009) 1.40
Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med (1985) 1.39
Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol (2000) 1.38
Diuretics, ACE inhibitors and NSAIDs--the triple whammy. Med J Aust (2000) 1.35
Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest (1999) 1.30
Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int (2000) 1.29
COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet (2008) 1.29
Juxtaglomerular cell complex in the regulation of renal salt excretion. Am J Physiol (1998) 1.27
Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology (1979) 1.26
Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther (2001) 1.26
Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med (2000) 1.24
The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes (2007) 1.24
Macrophages, monocyte chemoattractant peptide-1, and TGF-beta 1 in experimental hydronephrosis. Am J Physiol (1994) 1.24
Effect of prostaglandin E on immune complex nephritis in NZB/W mice. Lab Invest (1979) 1.24
Cyclooxygenase-2 in rat nephron development. Am J Physiol (1997) 1.24
Renal effects of COX-2-selective inhibitors. Am J Nephrol (2001) 1.24
MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther (2008) 1.23
Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria. Am J Physiol Renal Physiol (2004) 1.23
Drug combinations and impaired renal function -- the 'triple whammy'. Br J Clin Pharmacol (2005) 1.22
Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition. Am J Physiol Renal Physiol (2001) 1.22
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther (1999) 1.20
Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology (2009) 1.19
Ibuprofen interferes with the efficacy of antihypertensive drugs. A randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen. Ann Intern Med (1987) 1.18
Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest (2001) 1.17
Cytokine-induced production of monocyte chemoattractant protein-1 by cultured human mesangial cells. J Immunol (1992) 1.17
Dehydration activates an NF-kappaB-driven, COX2-dependent survival mechanism in renal medullary interstitial cells. J Clin Invest (2000) 1.16
Obstructive nephropathy in the rat: possible roles for the renin-angiotensin system, prostaglandins, and thromboxanes in postobstructive renal function. J Clin Invest (1980) 1.16
Renal papillary necrosis in juvenile rheumatoid arthritis. J Pediatr (1980) 1.14
Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest (1983) 1.14
Analgesic use and renal function in men. JAMA (2001) 1.13
Expression of mitogen-inducible cyclooxygenase induced by lipopolysaccharide: mediation through both mitogen-activated protein kinase and NF-kappaB signaling pathways in macrophages. Biochem Pharmacol (1997) 1.13
Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol (1989) 1.12
Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther (2002) 1.12
Increased expression of monocyte chemoattractant protein-1 in anti-thymocyte antibody-induced glomerulonephritis. Kidney Int (1993) 1.11
Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension (1999) 1.09
Prevention, incidence, and outcomes of contrast-induced acute kidney injury. Arch Intern Med (2008) 1.09
Renal hyperfiltration is a determinant of endothelial function responses to cyclooxygenase 2 inhibition in type 1 diabetes. Diabetes Care (2010) 1.08
Cyclooxygenase-2 mediates increased renal renin content induced by low-sodium diet. Hypertension (1997) 1.07
End-stage renal disease and non-narcotic analgesics: a case-control study. Br J Clin Pharmacol (1990) 1.07
Inhibition of macula densa-stimulated renin secretion by pharmacological blockade of cyclooxygenase-2. Am J Physiol (1999) 1.07
Over-the-counter analgesic use. J Am Soc Nephrol (2009) 1.06
NSAIDs and increased blood pressure. What is the clinical significance? Drug Saf (1997) 1.06
Role of p38 in the regulation of renal cortical cyclooxygenase-2 expression by extracellular chloride. J Clin Invest (2000) 1.05
Dexamethasone inhibits the induction of monocyte chemotactic-activating factor production by IL-1 or tumor necrosis factor. J Immunol (1991) 1.05
Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol Pathol (1998) 1.05
Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs. J R Soc Med (2001) 1.05
COX-2 and the kidney. J Cardiovasc Pharmacol (2006) 1.05
Regulation of monocyte chemoattractant protein-1 and macrophage colony-stimulating factor-1 by IFN-gamma, tumor necrosis factor-alpha, IgG aggregates, and cAMP in mouse mesangial cells. J Immunol (1993) 1.04
A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int (2000) 1.04
Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. Expert Opin Pharmacother (2003) 1.04
Epidemiologic study of regular analgesic use and end-stage renal disease. Arch Intern Med (1983) 1.04
COX-2 inhibition prevents downregulation of key renal water and sodium transport proteins in response to bilateral ureteral obstruction. Am J Physiol Renal Physiol (2005) 1.04
Glomerular expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis. Lab Invest (1994) 1.04